Pharmaceutical

Sonnet BioTherapeutics secures US patent covering two drug candidates

Sonnet BioTherapeutics has announced the issuance of US Patent No. 12,134,635 covering its two new drug candidates, SON-1411 and SON-1400, expected to advance treatment options for cancer.

Nov 9, 2024 - 06:00
Sonnet BioTherapeutics secures US patent covering two drug candidates
Sonnet BioTherapeutics has announced the issuance of US Patent No. 12,134,635 covering its two new drug candidates, SON-1411 and SON-1400, expected to advance treatment options for cancer.
Read the original article

Tags:

Previous Article

Mustang Bio’s MB-108 receives FDA orphan drug status for glioma treatment

Next Article

Santen, Arctic Vision sign deal for ARVN001 to treat UME

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

AbbVie’s RINVOQ now indicated for paediatric arthritis in US

AbbVie’s RINVOQ now indicated for paediatric arthritis ...

Jun 6, 2024

STAT+: Merck to acquire Prometheus Biosciences, maker of autoimmune drugs, for $10.8 billion

STAT+: Merck to acquire Prometheus Biosciences, maker o...

Apr 17, 2023

How pharmacy deserts are putting the health of Black and Latino Americans at risk

How pharmacy deserts are putting the health of Black an...

Nov 11, 2023